A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the efficacy and safety of different intra-articular (i.a.) dosages of sprifermin in subjects with primary osteoarthritis of the knee (FORWARD)

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the efficacy and safety of different intra-articular (i.a.) dosages of sprifermin in subjects with primary osteoarthritis of the knee (FORWARD)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Sprifermin (Primary)
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Acronyms FORWARD
  • Sponsors EMD Serono
  • Most Recent Events

    • 28 May 2015 Planned End Date changed from 1 Aug 2019 to 1 May 2019 as per ClinicalTrials.gov record.
    • 07 Aug 2013 Additional lead trial centres added as reported by ClinicalTrials.gov.
    • 07 Aug 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01919164).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top